Chai Discovery Signs Pfizer Deal, Eyes $3.4B Valuation

AI drug discovery startup Chai Discovery has secured a partnership with Pfizer, the company disclosed exclusively to Forbes, marking its second major pharmaceutical collaboration in recent months as it pursues a $400 million funding round that would value the young company at $3.4 billion.

The Pfizer deal follows a January agreement with Eli Lilly to design novel therapeutics using Chai's AI platform. Both partnerships center on the startup's antibody design model, which generated immediate industry response when released last June—just 15 months after the company's founding.

"It was like we dropped a bomb on the field," Chai cofounder and president Jack Dent told Forbes, noting that nearly 20 pharmaceutical companies reached out following the model's release. "People were messaging on LinkedIn at 2 a.m., saying, 'I am so excited I can't sleep.'"

Why it matters

The pharmaceutical industry faces a persistent challenge: developing a single drug typically requires more than a decade and costs over $1 billion. Chai's rapid ascent and ability to attract partnerships with industry giants like Eli Lilly (valued at $1 trillion market cap) and Pfizer ($63 billion in 2025 revenue) suggests its AI approach may offer a credible path toward faster, more precise drug development. If successful, such technology could address diseases currently considered "undruggable" while reducing the time and capital required to bring new therapies to market.

Rapid valuation climb

The startup's valuation trajectory reflects investor confidence in its technology. Chai Discovery reached a $1.3 billion valuation in January, according to Forbes. The company is now in discussions to raise $400 million in new venture capital funding at a $3.4 billion valuation—a substantial premium that would more than double its worth in less than six months.

Chai cofounder and CEO Josh Meier framed the company's mission as elevating pharmaceutical standards rather than simply accelerating production. "We want to raise the bar of medicines that are created," Meier said. "It's not just getting more medicines to patients, but better medicines."

Competing in a crowded field

Despite facing competitors with longer track records and deeper resources, Chai Discovery has positioned itself at the forefront of AI-driven drug discovery. The company's antibody design model represents a technical achievement in a field where AI's promise—to transform the laborious process of creating new therapies—has generated significant scientific and investor interest but remains largely unproven at scale.

The details of both the Eli Lilly and Pfizer partnerships, including financial terms and specific therapeutic targets, were not disclosed.

These developments were first reported by Forbes.